Four developments that shaped October
One feature per therapeutic area, chosen by patient impact from the studies and FDA approvals ENCLAI reported in October 2026. Every number checked against its source sentence.
Dr Natalya Mathur · Dr Anjali Mathur · Dr Mathur G · ENCLAI
October 2026 · 15 pages · Published by ENCLAI
In this issue
Women's & reproductive health · Systematic review / meta-analysisCCHF in pregnancy linked to 28.8% maternal death and 57.4% fetal loss in meta-analysisRead the full article →Oncology · Randomised trial, Phase 3Felzartamab plus lenalidomide-dexamethasone extends progression-free survival in relapsed or refractory multiple myelomaRead the full article →Neurology · ApprovalJUVMO approved for Parkinson’s disease in adultsRead the full article →Infectious disease · Randomised trialLong-acting HIV injections match oral pills for viral suppression in African adults with adherence challengesRead the full article →
Cite this issue
Dr Natalya Mathur, Dr Anjali Mathur, Dr Mathur G, ENCLAI. ENCLAI Evidence Digest — October 2026. ENCLAI; 2026. https://doi.org/10.5281/zenodo.23931904. ENCLAI ID ENCLAI-2026-0000752-8.
For healthcare and research professionals. This digest summarises published evidence and is not medical advice. Every number is checked against its exact source sentence; charts are drawn by code from verified values. Report an error to [email protected]; corrections are listed in the next issue.